SIGN UP FOR UPDATES!
Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
ENGLEMED
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BOOKS AND GIFTS THIS WAY!
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
SEARCH THIS SITE
Google

WWW Englemed
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
FreeDigitalPhotos
www.freedigitalphotos.net
FreeWebPhotos
www.freewebphoto.com
FROM OUR NEWS FEEDS
Treatment hope for cognitive symptoms in Parkinson's disease
Tues May 17th - Ultra-powerful 7T MRI scanners could help to identify those patients with conditions such as Parkinson's disease who would benefit from new treatments for cognitive symptoms that were previously untreatable, British researchers report today. More
E-cigarettes as effective as patches for pregnant women
Tues May 17th - E-cigarettes can help pregnant women to stop smoking and are as safe as nicotine patches, according to new UK research. More
RECENT COMMENTS
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote:
https://epidemicj17.imascientist.org.uk/2017/06/21... on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
ASTHMA & ALLERGY BOOKS
Clearing the air: An Assessment of Asthma and Indoor Allergens ABC of Asthma For more books click here
ALLERGY NEWS
ALLERGY RSS FEEDS
RSS graphic XML Graphic
ENGLEMED HEALTH NEWS

Psoriasis treatment for severe asthma worsens symptoms

Friday October 29th 2021

A psoriasis medication that was hoped could help patients with severe asthma actually worsened symptoms, a new global study has found.

The study, led by researchers at the UK’s National Institute for Health Research (NIHR) Leicester Biomedical Research Centre – a partnership between Leicester’s Hospitals, the University of Leicester and Loughborough University – examined the potential of risankizumab as a treatment.

The research, which was co-led by researchers in Manchester, Belgium and Canada, recruited 214 trial participants, of whom 105 were randomised to receive a risankizumab injection every four weeks over 24 weeks, while 109 patients received a placebo.

Writing in the New England Journal of Medicine, the team says the cohort treated with risankizumab had an average time-to-first-worsening symptoms of 40 days, compared to 86 days for the patients prescribed a placebo.

When they studied gene signatures from immune cells in airway samples, risankizumab was found to decrease the molecules that protect against infection.

Study lead Professor Chris Brightling, NIHR senior investigator, said: “It is always disappointing when a potential treatment is shown to be ineffective at treating a disease, more so when it makes symptoms worse.

“We think risankizumab reduces the presence of substances in the airways that are important factors in preventing infections, which probably makes the patients’ symptoms worse. This theory is backed by molecular profiling, which shows reduced levels of these substances in samples taken from patients on the trial.”

Risankizumab in Severe Asthma: A Phase IIa, Placebo-Controlled Study. New England Journal of Medicine 27 October 2021

[Research project]

Tags: Allergies & Asthma | Dermatology | Pharmaceuticals | UK News

Printer friendly page Printer friendly page

Comment on this article:

Name:
Email:
Comment:
<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)
CATEGORIES